Brief: Antengene Corp Says NMPA Approved Application For ATG-019 In Patients With Advanced Solid Tumors
07/04/2021 02:27
April 7 (Reuters) - Antengene Corp Ltd 6996.HK :
* NMPA APPROVED IND APPLICATION FOR ATG-019 IN PATIENTS WITH
ADVANCED SOLID TUMORS OR NON-HODGKIN'S LYMPHOMA
Source text for Eikon: []
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106